

Product datasheet for TL320291V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

CDK2 Human shRNA Lentiviral Particle (Locus ID 1017)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: CDK2 Human shRNA Lentiviral Particle (Locus ID 1017)

Locus ID: 1017

Synonyms: CDKN2; p33(CDK2)

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CDK2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001290230, NM 001798, NM 052827, NM 001798.1, NM 001798.2, NM 001798.3,

NM 001798.4, NM 052827.1, NM 052827.2, NM 052827.3, NM 001290230.1, BC003065,

BC003065.2, NM 001798.5, NM 001290230.2

UniProt ID: P24941

Summary: This gene encodes a member of a family of serine/threonine protein kinases that participate

in cell cycle regulation. The encoded protein is the catalytic subunit of the cyclin-dependent protein kinase complex, which regulates progression through the cell cycle. Activity of this protein is especially critical during the G1 to S phase transition. This protein associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B). Alternative splicing results in multiple transcript variants.

[provided by RefSeq, Mar 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact $\underline{\text{techsupport@origene.com}}$.

If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).